Latest / Decera Clinical Education Oncology Podcast
New Evidence With BTK Inhibitor Therapy in CLL From EHA 2023
In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at EHA 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL). The discussion includes analyses of:
CLL12: final results of the phase III trial of ibrutinib vs placebo in asymptomatic, treatment-naive CLL
SEQUOIA: extended follow-up of zanubrutinib vs BR in treatment-naive CLL
CAPTIVATE: 4-year follow-up from the fixed duration cohort of ibrutinib plus venetoclax in CLL/small lymphocytic lymphoma
Phase II trial of acalabrutinib plus obinutuzumab in treatment-naive CLL…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.